Patient Experience Data: Get Your Copy at DIA

Publication
Article
Applied Clinical TrialsApplied Clinical Trials-06-01-2023
Volume 32
Issue 6

Newly released book edited by Matt Reaney, (PhD, CPsychol, CSci, MSc), head, science and analytics, PCS, at IQVIA focuses on patient experience data with all levels of clinical research in mind.

IQVIA’s Patient Centered Solutions (PCS) team is distributing print copies of a newly released book, Using Patient Experience Data to Evaluate Medical Interventions. Generating, Understanding and Using Patient Experience Data Within and Alongside Clinical Trials, at the DIA meeting in Boston at the end of this month. If you are not on hand to pick up a complimentary copy, it will also be available for purchase at the Kindle store as an eBook.

Edited by Matt Reaney, (PhD, CPsychol, CSci, MSc), head, science and analytics, PCS, at IQVIA, the content is timely and the company believes it has the potential to become the authoritative text on patient-experience data (PED) in drug development. It was created with all levels and roles of clinical research in mind, with the intent to use the content to facilitate their work in bringing their products to the market.

Reaney outlines in Chapter 1, “Patient experience data (PED) in intervention development – what it is, why you should care, and how this book can help?” He writes, “The relevance of PED extends beyond patient­level healthcare and into the development of new interventions. Indeed, understanding PED in intervention development is an important precursor to patient-focused healthcare provision. The goal of intervention development has long been to maximize health and well-being, but it is only recently that developers and sponsors of intervention development have recognized the importance of the patient experience in achieving this goal.”

  • He continues to outline the reasons why PED could be considered confusing, why it is becoming more important and how it can be used effectively. For example, PED can help answer the following questions:
  • What signs and symptoms are most bothersome to patients?
  • How are patients' lives affected by disease and treatment?
  • How can we best understand treatment benefit?
  • Do patient preferences align with clinical priorities?
  • How well do typical trial endpoints align with outcomes that matter most to patients?
  • How do attitudes toward interventions vary by patient subgroup?

The book is broken down into four important sections of PED—generating, understanding, using, and developing a PED strategy. IQVIA contributing authors range the professional functions within the organization from PCS, to statistics, research, endpoints, and many more to reflect their expertise to the included sections.

Lisa Henderson, editor-in-chief, Applied Clinical Trials

Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Related Content
© 2024 MJH Life Sciences

All rights reserved.